2023-2024

CHBRP generally analyzes introduced bills prior to their first Senate or Assembly Health Committee hearing. Completed CHBRP analyses (and the analyzed bill language) are available at http://chbrp.org/analysis/completed-analyses. As bills move through the Legislature, bills may be significantly amended, which may alter CHBRP’s projected impacts. The table, below, indicates the current version of each analyzed bill and the extent to which CHBRP’s analyses remain relevant. Current bill language and the bill status are available at http://leginfo.legislature.ca.gov/.

CHBRP’s analyses may still be of use after the legislative cycle concludes in order to inform future legislation, the implementation of analyzed legislation that is signed into law or included in California’s budget, and the ongoing evaluation of relevant health benefit mandates and repeals.

The below is current as of 1/11/2024. 

Bill Current location Bill amended since CHBRP analysis? Which portions of CHBRP’s analysis remain relevant?
AB 85
(Weber): Social Determinants of Health: Screening and Outreach
Vetoed by the Governor - 10/07/23 Yes – 9/08/2023 All portions of CHBRP’s analysis remain relevant. Amended language would expand which health care professionals health plans/policies are required to provide information about access to, and could lead to more enrollees gaining access to these professionals and receiving services they otherwise would not have. Additionally, implementation of AB 85 would be delayed until 2026, with a report from the working group submitted in 2027. Language has also been added specifying reimbursement rates for FQHCs.
AB 620
(Connolly): Metabolic Disorders
Vetoed by the Governor - 10/07/23 Yes – 9/08/2023 All portions of CHBRP’s analysis remain relevant; however, the utilization and cost impacts may decrease due to amended bill language excluding coverage for special food products for people with chronic digestive disorders. Amended language delays implementation date by six months to July 1, 2024.
AB 716
(Boerner Horvath): Emergency Ground Medical Transportation
Approved by the Governor - 10/08/23 Yes – 9/6/2023 All portions of CHBRP’s analysis remain relevant.
AB 874
(Weber): Out-of-pocket Expenses
Assembly Health committee hearing postponed - 04/21/23 No All portions of CHBRP’s analysis remain relevant.
AB 907
(Lowenthal): Coverage for PANDAS and PANS
Vetoed by the Governor - 10/07/23 Yes – 7/03/2023 All portions of CHBRP’s analysis remain relevant.
AB 1048
(Wicks): Dental Benefits and Rate Review
Approved by the Governor - 10/08/23 Yes – 9/8/2023 All portions of CHBRP’s analysis remain relevant, however the fiscal impacts have been reduced due to the removal of prohibitions of waiting periods and preexisting conditions for dental plan products in the individual and small group markets. In addition, implementation is now delayed to 1/1/2025 vs 1/1/2024.
AB 1060
(Ortega): Naloxone Hydrochloride
Vetoed by the Governor - 10/07/23 Yes – 9/8/2023 All portions of CHBRP’s updated analysis published June 23, 2023 remain relevant.
AB 1157
(Ortega): Rehabilitative and Habilitative Services: Durable Medical Equipment and Services
Held under submission in the Senate - 09/01/23 Yes – 7/13/2023 Amended language would require the California Secretary of Health and Human Services to seek ways of implementing this mandate that would not exceed Essential Health Benefits in California. All portions of CHBRP’s analysis remain relevant.
AB 1288
(Reyes): Medication-Assisted Treatment
Vetoed by the Governor - 10/08/23 Yes – 7/13/2023 All portions of CHBRP’s analysis remain relevant. For commercial/CalPERS enrollees, amended language would additionally prohibit application of prior authorization or step therapy requirements to the coverage of naloxone products or another opioid antagonist approved by the United States Food and Drug Administration (FDA). An emergency intervention, opioid antagonists are used when an overdose appears to be occurring and naloxone is broadly distributed (without cost) by multiple organizations seeking to decrease overdose deaths and is available over-the-counter (without a prescription). As neither step therapy nor prior authorization requirements are likely to be applied to an emergency use medication that is broadly available without cost, the additional prohibitions are unlikely to have a measurable impact.
AB 1451
(Jackson): Behavioral Health Crisis Treatment
Vetoed by the Governor - 10/07/23 Yes – 7/13/2023 All portions of CHBRP’s analysis remain relevant.
AB 1645
(Zbur): Cost Sharing
Vetoed by the Governor - 10/07/23 Yes – 7/13/2023 Amended language would, for small group and individual market plans and policies, delay implementation of some requirements by 12 months. Amended language requires reimbursement of nonparticipating essential community providers at either the plan/insurer’s average contracted rate or 125% of the amount Medicare reimburses, whichever is greater. The inclusion of the rate related to Medicare and the requirement of using whichever is greater would result in some increased reimbursements, which would increase the impact on total expenditures from $20,065,000 to $23,237,000. All other portions of CHBRP’s analysis remain relevant.
SB 70
(Wiener): Prescription Drug Coverage
Held under submission in Assembly Health Committee - 09/01/23 Yes – 6/29/2023 All portions of CHBRP’s analysis remain relevant.
SB 90
(Wiener): Insulin Affordability
Vetoed by the Governor - 10/07/23 Yes– 9/6/2023 Amended language delays implementation in the small group and individual markets until 2025. All portions of CHBRP’s analysis remain relevant. 2025. Additionally, for individual and small group plans and policies, cost sharing limits are only applicable to insulin products covered under Tiers 1 and 2. It is possible this amended language would result in higher cost sharing for some portion of enrollees who’s insulin is covered under a higher tier.
SB 339
(Wiener): HIV Preexposure Prophylaxis and Postexposure Prophylaxis
Approved by the Governor - 2/6/24 Yes – 1/8/2024 Amended language would strike requirement for pharmacist services to be reimbursed at 100% of the fee schedule for physician services and instead require reimbursement for pharmacist services performed at in-network pharmacies and out-of-network pharmacies if the plan/insurer has an out-of-network pharmacy benefit. Estimated fiscal impacts may be reduced due to potentially lower reimbursement rates. All other portions of CHBRP’s analysis remain relevant.
SB 427
(Portantino): Antiretroviral Drugs, Devices, and Products
Assembly Appropriations: Ordered to inactive file on request of Assembly Member - 09/14/23 Yes – 9/8/2023 All portions of CHBRP’s analysis remain relevant.
SB 621
(Caballero): Biosimilar Drugs
Approved by the Governor - 10/08/23 Yes – 5/02/2023 All portions of CHBRP’s analysis remain relevant.
SB 635
(Menjivar and Portantino): Hearing Aids
Senate: Consideration of Governor's veto pending - 10/07/23 Yes – 7/13/2023 All portions of CHBRP’s analysis (which was based on June 8th amended language) remain relevant. The July 13th amendment delays implementation until 2025.
SB 694
(Eggman) Medi-Cal: Self-Measured Blood Pressure Devices and Services
Senate: Consideration of Governor's veto pending - 10/07/23 Yes – 9/01/2023 All portions of CHBRP’s analysis remain relevant.
SB 729
(Menjivar): Treatment for Infertility and Fertility Services
Hearing postponed by Assembly Health committee - 09/01/23 Yes – 8/14/2023 Amended language would require coverage of fertility services for large group plans and policies, and would require small group plans and policies to offer coverage for fertility services. Amended language specifies fertility services includes a maximum of three completed oocyte retrievals, and also adds an exemption for religious employers. Scenario 2 remains relevant, although impacts would likely be reduced marginally due to the exemption for religious employers.
SB 839
(Bradford) Obesity Parity Act
January 10 set for first hearing canceled at the request of author. No All portions of CHBRP’s analysis remain relevant.